- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
FDA Accepts BLA for Alvotech Ustekinumab Biosimilar
Alvotech, an Iceland-based company, announced that the FDA accepted its biologics license application (BLA) for its proposed ustekinumab biosimilar referencing Stelara. The company said it expects the FDA’s decision in the second half of 2023.
The FDA has accepted a biologics license application (BLA) for Alvotech’s ustekinumab biosimilar candidate (AVT04) referencing Stelara, which will be used to treat several autoimmune disorders, according to a statement from the company.
“The progress of AVT04 helps to validate the end-to-end biosimilars development and manufacturing platform that we have built at Alvotech…. Our approach is multi-product, and we look forward to broadening our portfolio as we continue to focus on expanding access to affordable biologic medicines,” said Joseph McClellan, chief scientific officer of Alvotech.
Ustekinumab products are monoclonal antibodies that act as inhibitors for interleukin (IL)-12 and IL-23. Stelara, developed by Janssen Pharmaceuticals, is indicated for the treatment of patients with psoriatic arthritis, plaque psoriasis, and inflammatory bowel disease, which is an umbrella term for ulcerative colitis and Crohn disease.
Alvotech has a commercialization partnership with Teva Pharmaceuticals, which will have exclusive rights to marketing AVT04 in the United States if it is approved. The companies anticipate the FDA’s final decision on AVT04 to come in the second half of 2023.
“We are pleased to be one step closer to making AVT04 available to patients and providers as a biosimilar treatment option to Stelara® for indicated inflammatory conditions…. Teva continues to remain focused on our commitment to lower healthcare costs and expand the availability and access of biosimilars,” commented Christine Baeder, senior vice president and chief operating officer of US Generics at Teva.
Alvotech and Teva’s partnership began in August 2020 and concerns 5 biosimilar candidates, including an adalimumab biosimilar (AVT02) referencing Humira. AVT02 is currently under review with the FDA and is expected to enter the US market in July 2022, along with 6 other adalimumab biosimilars.
In May 2022, Alvotech shared data that confirmed the clinical safety and efficacy of AVT04 compared to the reference product in patients with moderate to severe chronic plaque psoriasis as well as positive results from a phase 1 pharmacokinetic equivalence study.
Other Ustekinumab Biosimilars
The news comes after Janssen, a division of Johnson & Johnson and the owner of Stelara, sued Amgen over its ustekinumab biosimilar candidate. Janssen claimed that Amgen infringed on 2 of its patents when creating the biosimilar.
In addition to Alvotech and Amgen, California-based Rani Therapeutics is in the preclinical development staged for RT-111, a RaniPill Go capsule to administer an ustekinumab biosimilar. The RaniPill capsule would allow for oral delivery of the drug.
Biocon Biologics entered into a licensing agreement with Yoshindo for the commercialization of its ustekinumab biosimilar in Japan in October 2022. Formycon published positive phase 3 bioequivalence data for its ustekinumab biosimilar, for which the company acquired from ATHOS. Bio-Thera and Hikma Pharmaceuticals have also partnered to compete against Stelara with a biosimilar (BAT2206). Hikma would be in charge of US commercialization.
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
The Growing Impact of Biosimilars in IBD Care
April 23rd 2025Biosimilars are proving to be a game-changing solution in the fight against inflammatory bowel disease (IBD), offering a cost-effective alternative to biologics with similar efficacy and safety, while innovative drug delivery systems promise to further enhance treatment outcomes and accessibility for millions worldwide.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
Biosimilar and Biologic Use Increasing in Greek Patients With IBD
April 19th 2025A retrospective study from a single inflammatory bowel disease (IBD) center in Greece reported that from 2018 to 2022, the use of biologics increased by 28% yearly, and the proportion of patients using biosimilars grew from 33% to 67%.
